• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本分离的产β-内酰胺酶革兰阴性细菌对头孢他啶、头孢洛林和氨曲南-阿维巴坦联合用药的体外药敏研究

In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.

机构信息

Department of Microbiology and Infectious Diseases, Faculty of Medicine, Toho University School of Medicine, Tokyo 143-8540, Japan.

Department of Microbiology and Infectious Diseases, Faculty of Medicine, Toho University School of Medicine, Tokyo 143-8540, Japan.

出版信息

J Infect Chemother. 2015 Feb;21(2):148-51. doi: 10.1016/j.jiac.2014.08.028. Epub 2014 Oct 25.

DOI:10.1016/j.jiac.2014.08.028
PMID:25444674
Abstract

Avibactam displays potent inhibition of extended-spectrum, AmpC, KPC and some OXA β-lactamases. We examined the combinations of avibactam with ceftazidime, ceftaroline and aztreonam by the broth microdilution method against Gram-negative bacteria harboring molecularly-characterized β-lactamase genes collected in Toho University, Japan. Bacterial isolates included: Ambler class A β-lactamase-producing Enterobacteriaceae (n = 26); class C β-lactamase-producing Enterobacteriaceae (n = 9) and class D β-lactamase-producing Acinetobacter baumannii (n = 9) and Enterobacteriaceae (n = 3). Ceftazidime-avibactam, ceftaroline-avibactam ands aztreonam-avibactam were active against the strains with an extended-spectrum β-lactamase (ESBL) or AmpC enzymes, but combination with avibactam did not reduce β-lactam MICs against A. baumannii with OXA β-lactamases including carbapenemases, such as OXA-40 and -69.

摘要

阿维巴坦对广谱、AmpC、KPC 和一些 OXA 类β-内酰胺酶具有很强的抑制作用。我们用肉汤微量稀释法,检测了日本东海大学收集的具有分子特征β-内酰胺酶基因的革兰氏阴性菌中阿维巴坦与头孢他啶、头孢洛林和氨曲南的组合。细菌分离株包括:产 Ambler 类 A 内酰胺酶的肠杆菌科(n = 26);产 C 类β-内酰胺酶的肠杆菌科(n = 9)和产 D 类β-内酰胺酶的鲍曼不动杆菌(n = 9)和肠杆菌科(n = 3)。头孢他啶-阿维巴坦、头孢洛林-阿维巴坦和氨曲南-阿维巴坦对具有超广谱β-内酰胺酶(ESBL)或 AmpC 酶的菌株有效,但与阿维巴坦联合使用并不能降低对包括碳青霉烯酶在内的 OXA 类β-内酰胺酶的鲍曼不动杆菌的β-内酰胺 MIC 值,如 OXA-40 和 -69。

相似文献

1
In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.日本分离的产β-内酰胺酶革兰阴性细菌对头孢他啶、头孢洛林和氨曲南-阿维巴坦联合用药的体外药敏研究
J Infect Chemother. 2015 Feb;21(2):148-51. doi: 10.1016/j.jiac.2014.08.028. Epub 2014 Oct 25.
2
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.NXL104(阿维巴坦)联合β-内酰胺类药物对包括产 OXA-48 碳青霉烯酶肺炎克雷伯菌在内的革兰氏阴性菌的体外活性。
Int J Antimicrob Agents. 2012 Jan;39(1):86-9. doi: 10.1016/j.ijantimicag.2011.09.012. Epub 2011 Oct 29.
3
In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.头孢他啶、头孢洛林和氨曲南单独及与阿维巴坦联合对欧洲革兰氏阴性和革兰氏阳性临床分离株的体外活性。
Int J Antimicrob Agents. 2015 Jun;45(6):641-6. doi: 10.1016/j.ijantimicag.2014.12.033. Epub 2015 Feb 17.
4
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.头孢他啶/阿维巴坦对重症监护病房(ICU)和非 ICU 患者的革兰氏阴性菌进行了测试,包括呼吸机相关性肺炎患者。
Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14.
5
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.用阿维巴坦联合制剂检测已鉴定的产β-内酰胺酶菌株的体外敏感性。
Antimicrob Agents Chemother. 2015 Mar;59(3):1789-93. doi: 10.1128/AAC.04191-14. Epub 2014 Dec 22.
6
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.头孢他啶、头孢洛林和氨曲南单独及与阿维巴坦联合使用对表达选定单一β-内酰胺酶的同基因大肠杆菌菌株的活性。
Diagn Microbiol Infect Dis. 2015 May;82(1):65-9. doi: 10.1016/j.diagmicrobio.2015.02.003. Epub 2015 Feb 14.
7
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间,作为国际最佳耐药监测网络(INFORM)全球监测项目的一部分,分离出携带 OXA-48 酶的肠杆菌科细菌,对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
8
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.头孢洛林-阿维巴坦对革兰氏阴性菌群体的活性测试,包括表达一种或多种β-内酰胺酶和携带各种葡萄球菌盒式染色体 mec 类型的耐甲氧西林金黄色葡萄球菌的菌株。
Antimicrob Agents Chemother. 2012 Sep;56(9):4779-85. doi: 10.1128/AAC.00817-12. Epub 2012 Jun 25.
9
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.在法国一项前瞻性区域间调查中收集的碳青霉烯不敏感肠杆菌分离株的分子特征以及对新型头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂的敏感性
Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.
10
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.头孢他啶、头孢洛林和氨曲南与阿维巴坦联合应用对目标革兰氏阴性菌的抗生素后效应及β-内酰胺酶抑制剂后效应
Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.

引用本文的文献

1
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.鲍曼不动杆菌对碳青霉烯类耐药的地理分布及时间趋势:一项综合荟萃分析。
PLoS One. 2024 Dec 16;19(12):e0311124. doi: 10.1371/journal.pone.0311124. eCollection 2024.
2
Dissemination of Metallo-β-Lactamase-Producing in Serbian Hospital Settings: Expansion of ST235 and ST654 Clones.在塞尔维亚医院环境中传播的产金属β-内酰胺酶:ST235 和 ST654 克隆的扩展。
Int J Mol Sci. 2023 Jan 12;24(2):1519. doi: 10.3390/ijms24021519.
3
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.
头孢他啶/阿维巴坦耐药的细菌的分子机制。
WIREs Mech Dis. 2022 Nov;14(6):e1571. doi: 10.1002/wsbm.1571. Epub 2022 Jul 26.
4
In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Isolates from South Korea.头孢他啶-阿维巴坦和氨曲南-阿维巴坦对韩国碳青霉烯类耐药菌株的体外活性及接种量效应
Antibiotics (Basel). 2020 Dec 15;9(12):912. doi: 10.3390/antibiotics9120912.
5
New cephalosporins for the treatment of pneumonia in internal medicine wards.用于内科病房治疗肺炎的新型头孢菌素
J Thorac Dis. 2020 Jul;12(7):3747-3763. doi: 10.21037/jtd-20-417.
6
Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases.阿维巴坦与头孢他啶水解型 D 类β-内酰胺酶的相互作用。
Biomolecules. 2020 Mar 23;10(3):483. doi: 10.3390/biom10030483.
7
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.产超广谱β-内酰胺酶、AmpC 酶和碳青霉烯酶肠杆菌科细菌感染的治疗。
Clin Microbiol Rev. 2018 Feb 14;31(2). doi: 10.1128/CMR.00079-17. Print 2018 Apr.
8
Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.头孢他啶-阿维巴坦的药理学方面和作用谱:系统评价。
Infection. 2018 Apr;46(2):165-181. doi: 10.1007/s15010-017-1096-y. Epub 2017 Nov 7.
9
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦用于治疗复杂性腹腔内感染。
Ther Clin Risk Manag. 2016 Dec 1;12:1811-1826. doi: 10.2147/TCRM.S120811. eCollection 2016.
10
Recent Advances in the Rational Design and Optimization of Antibacterial Agents.抗菌药物合理设计与优化的最新进展
Medchemcomm. 2016 Sep 1;7(9):1694-1715. doi: 10.1039/C6MD00232C. Epub 2016 Jul 7.